Abstract
Objective: To estimate phenotypic and familial association between early-life injuries and attention-deficit/hyperactivity disorder (ADHD) and the genetic contribution to the association using polygenic risk score for ADHD (PRS-ADHD) and genetic correlation analyses. Methods: Children born in Denmark between 1995–2010 (n = 786,543) were followed from age 5 years until a median age of 14 years (interquartile range: 10–18 years). Using ICD-10 diagnoses, we estimated hazard ratios (HRs) and absolute risks of ADHD by number of hospital/emergency ward–treated injuries by age 5. In a subset of ADHD cases and controls born 1995 to 2005 who had genetic data available (n = 16,580), we estimated incidence rate ratios (IRRs) for the association between PRS-ADHD and number of injuries before age 5 and the genetic correlation between ADHD and any injury before age 5. Results: Injuries were associated with ADHD (HR = 1.61; 95% CI, 1.55–1.66) in males (HR = 1.59; 1.53–1.65) and females (HR = 1.65; 1.54–1.77), with a dose-response relationship with number of injuries. The absolute ADHD risk by age 15 was 8.4% (3+ injuries) vs 3.1% (no injuries). ADHD was also associated with injuries in relatives, with a stronger association in first- than second-degree relatives. PRS-ADHD was marginally associated with the number of injuries in the general population (IRR = 1.06; 1.00–1.14), with a genetic correlation of 0.53 (0.21–0.85). Conclusions: Early-life injuries in individuals and their relatives were associated with a diagnosis of ADHD. However, even in children with the most injuries, more than 90% were not diagnosed with ADHD by age 15. Despite a low positive predictive value and that the impact of unmeasured factors such as parental behavior remains unclear, results indicate that the association is partly explained by genetics, suggesting that early-life injuries may represent or herald early behavioral manifestations of ADHD.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 21m14033 |
Tidsskrift | Journal of Clinical Psychiatry |
Vol/bind | 83 |
Udgave nummer | 1 |
Antal sider | 19 |
ISSN | 0160-6689 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:Submitted: April 9, 2021; accepted September 7, 2021. Published online: January 4, 2022. Potential conflicts of interest: None. Funding/support: This study was funded by grants from Novo Nordisk Foundation (NNF16OC0022018), the Lundbeck Foundation (iPSYCH grant R248-2017-2003), and the Stanley Medical Research Institute and supported by CIRRAU. Dr Dalsgaard’s research is further supported by grants from National Institutes of Health (R01, grant ES026993), the European Commission (Horizon 2020, grant 667302), Helsefonden (grant 19-8-0260), and the European Union’s Horizon 2020 research and innovation programme under grant agreement 847879. The Wellcome Trust provided additional funding for Drs Riglin and Thapar (204895/Z/16/Z). Data handling and analysis on the GenomeDK HPC facility were supported by National Institute of Mental Health (1U01MH109514-01 to Dr Børglum) and Center for Genomics and Personalized Medicine (grant to Dr Børglum). Dr Børglum’s research was further supported by the European Community Horizon 2020 Programme (grant 667302). Role of the sponsor: The supporting sources had no role in the design, conduct, and reporting of the study. Supplementary material: Available at PSYCHIATRIST.COM
Publisher Copyright:
© Copyright 2022 Physicians Postgraduate Press, Inc.